肺癌中 70 %～ 80 %为非小细胞肺癌 ,而大多数患者确诊时已超越了根治性切除的范围 ,加之中晚期非小细胞肺癌对化疗不敏感 ,因此寻找对肺癌有较好疗效的化疗方案 ,加强综合治疗 ,是当前急需研究的课题。我科自 1996年 12月至 1999年 12月采用西艾克[1,2 ] ,联合表阿霉素、丝裂 70% to 80% of lung cancers are non-small cell lung cancers, and most patients have already exceeded the scope of radical resection when they are diagnosed. Plus middle and late stage non-small cell lung cancers are not sensitive to chemotherapy, so they are looking for chemotherapy with good curative effect on lung cancer. The plan to strengthen comprehensive treatment is an urgent need for research. In our department, we used Xiaike [1,2] from December 1996 to December 1999 to combine epirubicin and mitomycin